IBA SA : IBA Announces Full Year Results 2013 Web Conference Details

IBA Announces Full Year Results 2013 Web Conference Details

Louvain-la-Neuve, Belgium, March 13, 2014 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it will issue its business update and financial results for the 2013 financial year on Wednesday, March 26, 2014.

Conference Call Information

IBA will host a webcast conference call and Q&A session at 2pm CET / 1pm GMT / 9am EDT on Wednesday, March 26 2014. Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host the call, which will be conducted in English. The conference call details will also be included in the annual results statement to be published on March 26 at 7am CET.

The conference call will be webcast live and may be accessed on the event page here or through the IR page of the IBA website at: www.iba-worldwide.com. If you would like to participate in the Q&A, please dial:

UK                                        +44 (0)20 7750 99 26

Belgium                                +32 (0)2 404 03 05

The Netherlands        +31 (0)20 713 34 88

Luxembourg                +352 2786 01 66

United States                +1 914 885 07 79

France                                +33 (0)1 72 04 00 33

PIN code 59142416#

The presentation will be available on the Company's website shortly after the call.

- Ends -

 About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment.  IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions.  IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets.  The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com